Date: 2013-10-11
Type of information: Private placement
Company: Hybrigenics (France)
Investors: Pradeyrol Development (France)
Amount: € 1.3 million
Funding type: private placement
Planned used: Hybrigenics has just acquired the genomic activities of Imaxio and these funds will be used to finance the future growth of its genomic services.
Others: * On October 11, 2013, Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new treatments of proliferative diseases and specialised in protein interactions, has announced a € 1.3 million fund raising through a private placement reserved to Pradeyrol Development, a family office and majority shareholder of Imaxio. With 2.5 million newly issued shares representing 11.4% of Hybrigenics’ capital, PRD becomes Hybrigenics’ reference shareholder and is granted one observer seat on Hybrigenics’ Board of Directors.
Therapeutic area:
